Cancer Specialists of North Florida

Clinical research site in Jacksonville, Florida · 9822 TAPESTRY PARK CIR STE 201, JACKSONVILLE, FL 32246-9260 · (954) 927-1776 · Website

Part of Cancer Specialists of North Florida

As of July 2026, 16 paid clinical trials are recruiting at Cancer Specialists of North Florida in Jacksonville, Florida. Active studies at this site cover conditions such as Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer and Acinar Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Cancer Specialists of North Florida (16)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Advanced Non-Small Cell Lung Cancer

186 locations incl. Bullhead City

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222566·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

54 locations incl. Daphne

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

37 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for Breast Cancer

54 locations incl. Phoenix

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06790693·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

for Carcinoma, Non-Small-Cell Lung

51 locations incl. Birmingham

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06875310·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

for Oligometastatic Prostate Cancer (OMPC)

40 locations incl. Fayetteville

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

37 locations incl. Birmingham

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

for Cancer

24 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18 - 99

Code: NCT06207032·Recruiting·Listed Jan 2024

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

34 locations incl. Birmingham

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

15 locations incl. Springdale

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07155187·Phase 2, Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

for Hepatocellular Carcinoma (HCC)

11 locations incl. Glendale

Sponsor: Shanghai Henlius Biotech

Sex: All·Age: 18 - 65

Code: NCT07176650·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma (MM)

9 locations incl. Springdale

Sponsor: Shanghai Henlius Biotech

Sex: All·Age: 18+

Code: NCT07477587·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

More research sites in Jacksonville

Mayo Clinic in Florida (174 trials)
Mayo Clinic (81 trials)
Mayo Clinic Florida (72 trials)
Mayo Clinic Jacksonville (42 trials)
Nemours Children's Clinic-Jacksonville (32 trials)
Jacksonville Center for Clinical Research (21 trials)
Baptist MD Anderson Cancer Center (17 trials)
University of Florida (13 trials)
Brooks Rehabilitation (9 trials)
Mayo Clinic - Florida (9 trials)

Explore more

Paid clinical trials in Jacksonville, FL · Florida clinical trials